Article
Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk.
Cancer research - 15 Jun 2006
El-Zein Randa A, Schabath Matthew B, Etzel Carol J, Lopez Mirtha S, Franklin Jamey D, Spitz Margaret R
Abstract excerpt
In this case-control study, we modified the cytokinesis-block micronucleus (CBMN) assay, an established biomarker for genomic instability, to evaluate susceptibility to the nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by measuring the frequency of NNK-induced chromosomal damage endpoints (micronuclei, nucleoplasmic bridges, and nuclear buds) per 1,000 binucleated lymphocytes....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
